SCHEMBL12922012

SCHEMBL12922012

CNC(=O)c1nnc(Cc2ccsc2)c2cc(-c3ccc(Cl)cc3)sc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CHEK1 O14757 2/20 0.39
JAK2 O60674 4/20 0.37
JAK1 P23458 4/20 0.37
TYK2 P29597 4/20 0.37
JAK3 P52333 4/20 0.37
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
GFER P55789 1/20 0.35
KMT2A Q03164 1/20 0.35
MAP3K8 P41279 2/20 0.35
STK17B O94768 1/20 0.35
SNCA P37840 2/20 0.34
NPC1 O15118 2/20 0.34
POLB P06746 2/20 0.34
MALT1 Q9UDY8 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14038890 0.91 JAK2 (0.46) RAB9ASMN1; SMN2JAK2JAK1TYK2
SCHEMBL8827896 0.88 CHEK1 (0.47) GAARAB9ACHEK1ALDH1A1KDM4E
SCHEMBL12922031 0.88 MAPT (0.42) GAAALDH1A1MEN1MAPTKMT2A
SCHEMBL12922010 0.87 CHEK1 (0.38) GAARAB9ASMN1; SMN2CHEK1JAK2
SCHEMBL12922014 0.83 CHEK1 (0.40) GAARAB9ASMN1; SMN2CHEK1JAK2
SCHEMBL29012212 0.83 CHEK1 (0.40) GAARAB9ASMN1; SMN2CHEK1ALDH1A1
SCHEMBL12948533 0.83 CHEK1 (0.40) GAARAB9ASMN1; SMN2CHEK1JAK2
SCHEMBL12922002 0.83 FLT1 (0.45) SMN1; SMN2CHEK1JAK2JAK1TYK2
SCHEMBL13085878 0.82 NPC1 (0.36) GAARAB9ASMN1; SMN2CHEK1ALDH1A1
SCHEMBL8835436 0.80 JAK2 (0.40) GAARAB9ASMN1; SMN2CHEK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962626-B2 Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) 2015-02-24 US disclosed
US-8962626-B2 Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) 2015-02-24 US disclosed
US-20110009415-A1 Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses WU, ZHANGGUI (CN) 2011-01-13 US disclosed
US-20110009415-A1 Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses WU, ZHANGGUI (CN) 2011-01-13 US disclosed
EP-2241569-A1 THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) 2010-10-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009415-A1 Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses CYP3A5, ABCC5, DPYD GAA 4591/4885RAB9A 2331/4885SMN1; SMN2 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.